A fi­nal flop sig­nals the bit­ter end to Cir­cas­sia’s big plans for al­ler­gy R&D

Re­mem­ber the big plans Cir­cas­sia {LSE: CIR} had for its al­ler­gy drug pipeline when it went pub­lic, rais­ing $333 mil­lion in 2014 with promis­es of big things to come for in­vestors?

It didn’t work out. In fact, it was a com­plete bust.

Their Phase IIb has now wrapped for a house dust mite al­ler­gy rem­e­dy, and it failed like the rest of the stud­ies. So Ox­ford, UK-based Cir­cas­sia is pack­ing it in, and switch­ing over to a res­cue strat­e­gy pre­sent­ed by As­traZeneca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.